实用癌症杂志
實用癌癥雜誌
실용암증잡지
The Practical Journal of Cancer
2015年
8期
1215-1217
,共3页
胃癌%希罗达%顺铂%放疗%化疗%放化疗
胃癌%希囉達%順鉑%放療%化療%放化療
위암%희라체%순박%방료%화료%방화료
Cancer%Capecitabine%Cisplatin%Radiotherapy%Chemotherapy%Radiochemotherapy
目的 比较胃癌术后单纯化疗与胃癌术后同步放化疗的疗效及不良反应. 方法 将57例胃癌术后患者随机分为单纯化疗组与同步放化疗组,单纯化疗组采用6个周期XP方案(希罗达2 000 mg/m2 d1~14+顺铂60 mg/m2 d1 q3w). 同步放化疗组(第一阶段:2个周期XP方案化疗、第二阶段:放疗+希罗达1 650 mg/m2 5w、第三阶段:2个周期XP方案化疗). 结果 同步放化疗组28例患者术后1、2、3、5年生存率为75.0%、64.3%、57.1%、46.4%;单纯化疗组29例患者术后1、2、3、5年生存率为65.5%、51.7%、32.1%、21.4%,两组不良反应主要包括白细胞减少、血小板减少、贫血恶心、呕吐、腹泻、外周神经毒性及手足综合征,且以1、2度为主,同步放化疗组白细胞减少、恶心呕吐、手足综合征发生率高于单纯化疗组,但可耐受. 结论 胃癌术后同步放化疗组1、2、3、5 年生存率高于单纯化疗,且3、5年生存率有统计学意义,不良反应可耐受.
目的 比較胃癌術後單純化療與胃癌術後同步放化療的療效及不良反應. 方法 將57例胃癌術後患者隨機分為單純化療組與同步放化療組,單純化療組採用6箇週期XP方案(希囉達2 000 mg/m2 d1~14+順鉑60 mg/m2 d1 q3w). 同步放化療組(第一階段:2箇週期XP方案化療、第二階段:放療+希囉達1 650 mg/m2 5w、第三階段:2箇週期XP方案化療). 結果 同步放化療組28例患者術後1、2、3、5年生存率為75.0%、64.3%、57.1%、46.4%;單純化療組29例患者術後1、2、3、5年生存率為65.5%、51.7%、32.1%、21.4%,兩組不良反應主要包括白細胞減少、血小闆減少、貧血噁心、嘔吐、腹瀉、外週神經毒性及手足綜閤徵,且以1、2度為主,同步放化療組白細胞減少、噁心嘔吐、手足綜閤徵髮生率高于單純化療組,但可耐受. 結論 胃癌術後同步放化療組1、2、3、5 年生存率高于單純化療,且3、5年生存率有統計學意義,不良反應可耐受.
목적 비교위암술후단순화료여위암술후동보방화료적료효급불량반응. 방법 장57례위암술후환자수궤분위단순화료조여동보방화료조,단순화료조채용6개주기XP방안(희라체2 000 mg/m2 d1~14+순박60 mg/m2 d1 q3w). 동보방화료조(제일계단:2개주기XP방안화료、제이계단:방료+희라체1 650 mg/m2 5w、제삼계단:2개주기XP방안화료). 결과 동보방화료조28례환자술후1、2、3、5년생존솔위75.0%、64.3%、57.1%、46.4%;단순화료조29례환자술후1、2、3、5년생존솔위65.5%、51.7%、32.1%、21.4%,량조불량반응주요포괄백세포감소、혈소판감소、빈혈악심、구토、복사、외주신경독성급수족종합정,차이1、2도위주,동보방화료조백세포감소、악심구토、수족종합정발생솔고우단순화료조,단가내수. 결론 위암술후동보방화료조1、2、3、5 년생존솔고우단순화료,차3、5년생존솔유통계학의의,불량반응가내수.
Objective To compare the effects and adverse reactions of chemotherapy and three dimensional conformal radiotherapy(3D-CRT) plus chemotherapy for postoperative patients on gastric cancer.Methods 57 patients with gastric cancer after surgery were randomly divided into chemotherapy group and 3D-CRT plus chemotherapy group.29 cases of chemotherapy group received 6 cycles of XP(capecitabine 2 000 mg/m2 per day on days 1 to 14 and cisplatin 60 mg/m2 on day 1,repeated ev-ery 3 weeks) chemotherapy.28 cases of 3D-CRT plus chemotherapy group received 2 cycles of XP followed by 45-Gy XRT ( capecitabine 1 650 mg/m2 per day for 5 weeks) and 2 cycles of XP.Results 1-,2-,3-and 5-year survival rates of radiochemo-therapy group was 75.0%、64.3%、57.1%、46.4%.The chemotherapy group was 65.5%、51.7%、32.1%、21.4%.Adverse re-actions included decreased white cells,decreased platelet,anemia,nausea,vomiting,diarrhea,peripheral nerve toxicity and hand-foot syndrome,and mainly were at grades 1、2.Decreased white cells,nausea,vomiting and hand-foot syndrome in radiochemother-apy group were significantly higher than those of the chemotherapy group,Those adverse reactions of radiochemotherapy were tol-erable.Conclusion 1-,2-,3-and 5-year survival rates of radiochemotherapy group are higher than those of the chemotherapy group.The difference of 3 and 5-year survival rates are statistically significant.Adverse reactions of radiochemotherapy were toler-able.
